

MediPrint™ Ophthalmics Notches Up Another Clinical Success: Reports 43% Improvement in Comfort for Contact Lens Dropouts

US multisite study shows MediPrint's digitally printed HA lens significantly improves comfort for patients who had stopped wearing contact lenses.

SAN DIEGO, CA, UNITED STATES,
September 15, 2026 /

EINPresswire.com/ -- [MediPrint](#)



[Ophthalmics](#) Inc. today announced results from its US multisite clinical study, demonstrating a 43% improvement in Contact Lens Dry Eye Questionnaire (CLDEQ) score among contact lens dropouts. The study of 16 patients evaluated the daily disposable MediPrint HA lens, which incorporates a digitally printed, sustained release hyaluronic acid (HA) reservoir on the lens surface.



These are not just products - this is a platform and category shift where therapy is in the eye, making it a wearable medicine."

Praful Doshi, Founder and CEO of MediPrint Ophthalmics

The result adds to a growing body of clinical evidence for MediPrint's platform, which has now demonstrated positive outcomes for contact lens comfort and glaucoma indications across four separate studies, reinforcing the company's position as a leader in sustained ocular drug delivery through digital lens printing.

Building on this result, MediPrint plans to advance a

Weekly Disposable HA lens designed to extend comfort, convenience and cost efficiency for wearers, a direction industry veterans see as the next major shift in the category.

"A weekly MediPrint HA Lens is the next big thing for contact lens industries, much like we saw with the development of the hard contact lens, soft contact lens, gas permeable lens and daily disposable lens," said Tom Bender, former CEO and Chairman of Cooper Companies.

MediPrint's leadership frames the opportunity even more broadly: "These are not just products - this is a platform and category shift where therapy is in the eye, making it a wearable medicine," said Praful Doshi, Founder and CEO of MediPrint Ophthalmics.

Addressing Contact Lens Dropout

Contact lens dropout remains one of the most persistent and costly challenges in eyecare, with more than 18-22% of wearers discontinuing contact lens use every year. Dryness and discomfort remain the leading causes of dropout. The MediPrint HA lens targets this unmet need with continuous hydration and improved lubrication.

Advancing Sustained Delivery Platform for Ocular Drugs with HA

MediPrint has previously completed three Phase II Glaucoma trials, demonstrating a 30% reduction in IOP using its preservative-free weekly disposable lens with sustained delivery of bimatoprost and HA. With four successful clinical studies, MediPrint plans to first seek FDA approval for its Daily and Weekly Disposable HA lens in 2027 and 2028 respectively, followed by approvals for its therapeutic pipeline of glaucoma and dry eye treatment.

Partnering for Global Commercialization

With four successful clinical studies complete and a broad patent estate in place, MediPrint is actively pursuing strategic or equity partnerships to advance its wearable medicine platform. By combining the familiarity and convenience of contact lenses with sustained, non-invasive drug delivery, MediPrint has the potential to expand the contact lens application from a vision-correction device into a therapeutic platform.

IP Strength and Manufacturing Readiness

MediPrint Ophthalmics' technology is protected by a comprehensive global patent portfolio of 29 issued patents. The company operates a GMP compliant, manufacturing ready facility in San Diego, CA, providing a foundation for clinical development, manufacturing scale-up and commercialization.

About MediPrint Ophthalmics

MediPrint Ophthalmics stands at the forefront of ophthalmic innovation as a clinical stage company revolutionizing ocular drug delivery with its digital platform technology. With a steadfast commitment to enhancing comfort and offering non-invasive and effective treatment options to patients suffering from ocular diseases, MediPrint is developing digitally printed contact lenses with sustained release of HA and other therapeutic agents to the ocular surface. Its platform is validated with four successful clinical studies. MediPrint Ophthalmics' robust product pipeline is primarily focused on contact lens comfort, glaucoma management, and dry eye treatment to start.

Praful Doshi

MediPrint™ Ophthalmics

+1 858-335-2873

pdoshi@mediprintlens.com

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/940731769>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.